Published in PLoS One on February 21, 2012
Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study. World J Gastroenterol (2015) 0.76
Genomic Diversity of Hepatitis B Virus Infection Associated With Fulminant Hepatitis B Development. Hepat Mon (2015) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
HOMOTRANSPLANTATION OF THE LIVER IN HUMANS. Surg Gynecol Obstet (1963) 10.22
Global control of hepatitis B virus infection. Lancet Infect Dis (2002) 3.74
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology (2007) 2.20
From hepatitis to hepatoma: lessons from type B viral hepatitis. Science (1993) 2.15
Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology (2011) 1.89
High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology (2006) 1.87
Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology (2010) 1.77
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol (2011) 1.74
Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant (2010) 1.67
Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology (1998) 1.48
Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology (2003) 1.47
Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology (2008) 1.30
Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl (2004) 1.29
Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology (2000) 1.24
Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology (1991) 1.21
Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol (2001) 1.20
The hepatitis B virus and common mutants. Semin Liver Dis (2003) 1.18
Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology (2002) 1.11
Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl (2007) 1.10
Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl (2005) 1.06
An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl (2000) 1.05
Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl (2009) 1.05
Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl (2000) 1.04
Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl (2002) 1.02
High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant (2010) 0.94
Pretransplantation pre-S2 and S protein heterogeneity predisposes to hepatitis B virus recurrence after liver transplantation. Liver Transpl (2002) 0.89
Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant (2006) 0.88
Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives? Liver Transpl (2008) 0.87
Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl (2007) 0.83
Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl (2008) 0.83
Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B. Am J Transplant (2005) 0.81
Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes. Liver Transpl (2008) 0.81
Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg (1997) 0.80
Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol (2008) 0.78
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell (2009) 6.97
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. Hepatology (2011) 2.93
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology (2002) 2.83
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther (2012) 2.05
Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination. Gastroenterology (2012) 1.97
Label-free assays on the BIND system. J Biomol Screen (2004) 1.92
Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology (2004) 1.85
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol (2009) 1.82
IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol (2011) 1.80
Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology (2010) 1.77
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des (2011) 1.68
Encapsulation is a significant prognostic factor for better outcome in large hepatocellular carcinoma. J Surg Oncol (2012) 1.63
No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther (2004) 1.62
Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology (2006) 1.62
Predictors of long-term disease-free survival after resection of hepatocellular carcinoma: two decades of experience at Chang Gung Memorial Hospital. Ann Surg Oncol (2003) 1.60
Team physicians in college athletics. Am J Sports Med (2005) 1.57
Adverse outcomes in patients with postoperative ascites after liver resection for hepatocellular carcinoma. World J Surg (2012) 1.56
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther (2011) 1.51
Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation. Ann Surg Oncol (2011) 1.50
Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol (2002) 1.47
Lifestyle risk factors for intrahepatic stone: findings from a case-control study in an endemic area, Taiwan. J Gastroenterol Hepatol (2007) 1.41
Determinants for sustained HBeAg response to lamivudine therapy. Hepatology (2003) 1.38
Cholangiographic spectrum of intraductal papillary mucinous neoplasm of the bile ducts. Ann Surg (2006) 1.36
Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. Ann Surg Oncol (2003) 1.34
IgG4-positive plasma cells in cutaneous Rosai-Dorfman disease: an additional immunohistochemical feature and possible relationship to IgG4-related sclerosing disease. J Cutan Pathol (2009) 1.34
Foot strike and injury rates in endurance runners: a retrospective study. Med Sci Sports Exerc (2012) 1.34
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study. Hepatology (2012) 1.31
Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood (2008) 1.28
Hepatic resection for hepatocellular carcinoma with obstructive jaundice due to biliary tumor thrombi. World J Surg (2004) 1.28
A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PLoS One (2011) 1.27
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther (2011) 1.25
Reliability of a new ultrasonic cardiac output monitor in recipients of living donor liver transplantation. Liver Transpl (2008) 1.23
Adenosquamous/squamous cell carcinoma of the gallbladder. J Surg Oncol (2007) 1.16
Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery (2009) 1.16
Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PLoS One (2012) 1.14
Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One (2012) 1.10
Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int (2010) 1.10
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem (2009) 1.10
Regulatory T cells in transplantation. Semin Immunol (2006) 1.10
Spontaneous rupture of solid pseudopapillary neoplasm of the pancreas during pregnancy. Obstet Gynecol (2013) 1.09
Dominant tolerance: activation thresholds for peripheral generation of regulatory T cells. Trends Immunol (2005) 1.07
In-line radiofrequency ablation to minimize blood loss in hepatic parenchymal transection. Am J Surg (2005) 1.05
Characterization of intrahepatic cholangiocarcinoma of the intraductal growth-type and its precursor lesions. Hepatology (2005) 1.05
Scoring short-term mortality after liver transplantation. Liver Transpl (2010) 1.05
Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist (2011) 1.04
Comparison of murine cirrhosis models induced by hepatotoxin administration and common bile duct ligation. World J Gastroenterol (2005) 1.04
Pedunculated hepatocellular carcinoma: clinicopathologic study of 18 surgically resected cases. World J Surg (2002) 1.03
Epicardial ablation of rotors suppresses inducibility of acetylcholine-induced atrial fibrillation in left pulmonary vein-left atrium preparations in a beagle heart failure model. J Am Coll Cardiol (2011) 1.03
Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res (2012) 1.03
The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells. J Immunol (2012) 1.03
Enhancing structural support of the dermal microenvironment activates fibroblasts, endothelial cells, and keratinocytes in aged human skin in vivo. J Invest Dermatol (2012) 1.03
Surgical management of giant hepatic hemangiomas: complications and review of the literature. Chang Gung Med J (2012) 1.02
Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J Clin Microbiol (2002) 1.02
Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res (2011) 1.02
Standard radical gastrectomy in octogenarians and nonagenarians with gastric cancer: are short-term surgical results and long-term survival substantial? J Gastrointest Surg (2012) 1.02
The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther (2008) 1.02
CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer (2009) 1.02
Frameless angiogram-based stereotactic radiosurgery for treatment of arteriovenous malformations. Int J Radiat Oncol Biol Phys (2012) 1.00
Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg (2012) 1.00
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors. Bioorg Med Chem Lett (2008) 1.00
Pre-operative risk factors predict post-operative respiratory failure after liver transplantation. PLoS One (2011) 1.00
Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: univariate and multivariate analysis. World J Surg (2003) 1.00
Clinical and neuroanatomical predictors of cerebellar mutism syndrome. Neuro Oncol (2012) 0.99
ES-cell derived hematopoietic cells induce transplantation tolerance. PLoS One (2008) 0.99
Increasing expression of gastrointestinal phenotypes and p53 along with histologic progression of intraductal papillary neoplasia of the liver. Hum Pathol (2002) 0.98
Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol (2005) 0.98
Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol (2011) 0.98
Localization of Broca's area using verb generation tasks in the MEG: validation against fMRI. Neurosci Lett (2010) 0.96
Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer (2011) 0.95
Network analysis and proteomic identification of vimentin as a key regulator associated with invasion and metastasis in human hepatocellular carcinoma cells. J Proteomics (2012) 0.95
MEG event-related desynchronization and synchronization deficits during basic somatosensory processing in individuals with ADHD. Behav Brain Funct (2008) 0.95
The impact of CD4+ CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma. Surgery (2011) 0.95
Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence? J Gastrointest Surg (2011) 0.95
Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One (2011) 0.95
Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology (2012) 0.94
Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther (2011) 0.94
Modified endoscopic submucosal dissection with enucleation for treatment of gastric subepithelial tumors originating from the muscularis propria layer. BMC Gastroenterol (2012) 0.94
Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int (2007) 0.94
Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment. World J Surg Oncol (2011) 0.94
Surgical results in patients with hepatitis virus-related hepatocellular carcinoma in Taiwan. World J Surg (2002) 0.94
Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother (2013) 0.94